Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TT 223 + Epidermal growth factor analogue

Drug Profile

TT 223 + Epidermal growth factor analogue

Alternative Names: E1-I.N.T™; G1 + EGF analogue; TT-223 + EGF; TT-223 + EGF analogue

Latest Information Update: 27 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transition Therapeutics
  • Class Antihyperglycaemics; Gastrointestinal hormones; Growth factors; Neuropeptides; Peptide hormones
  • Mechanism of Action Epidermal growth factor stimulants; Gastrin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 17 Sep 2010 Discontinued - Phase-II for Type-1 diabetes mellitus in USA (SC)
  • 17 Sep 2010 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (SC)
  • 14 Mar 2008 Transition Therapeutics and Eli Lilly enter into a licensing and collaboration agreement for gastrin-based therapies in Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top